Mannkind Corp. (MNKD)

$4.18

-0.01

(-0.24%)▲

Market is closed - opens 7 PM, 26 Apr 2024

Insights on Mannkind Corp.

  • Increasing Revenue

    Revenue is up for the last 8 quarters, 11.99M → 58.47M (in $), with an average increase of 19.0% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 1.72M → 1.40M (in $), with an average decrease of 18.6% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 52.5% return, outperforming this stock by 43.4%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 239.5% return, outperforming this stock by 253.0%

Performance

  • $4.13
    $4.24
    $4.18
    downward going graph

    1.32%

    Downside

    Day's Volatility :2.71%

    Upside

    1.42%

    downward going graph
  • $3.17
    $5.75
    $4.18
    downward going graph

    24.16%

    Downside

    52 Weeks Volatility :44.87%

    Upside

    27.3%

    downward going graph

Returns

PeriodMannkind Corp.Sector (Health Care)Index (Russel 2000)
3 Months
24.78%
0.5%
0.0%
6 Months
3.47%
11.7%
0.0%
1 Year
9.14%
6.2%
2.2%
3 Years
-13.46%
13.5%
-23.0%

Highlights

Market Capitalization
1.1B
Book Value
- $0.91
Earnings Per Share (EPS)
-0.04
PEG Ratio
-0.23
Wall Street Target Price
7.08
Profit Margin
-6.0%
Operating Margin TTM
18.19%
Return On Assets TTM
1.72%
Return On Equity TTM
0.0%
Revenue TTM
199.0M
Revenue Per Share TTM
0.75
Quarterly Revenue Growth YOY
62.2%
Gross Profit TTM
42.3M
EBITDA
15.1M
Diluted Eps TTM
-0.04
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.13
EPS Estimate Next Year
0.25
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.01

Analyst Recommendation

Buy
    83%Buy
    16%Hold
    0
    0%Sell
Based on 12 Wall street analysts offering stock ratings for Mannkind Corp.(by analysts ranked 0 to 5 stars)
Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
9
9
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 69.38%

Current $4.18
Target $7.08

Company Financials

FY18Y/Y Change
Revenue
27.9M
↑ 137.2%
Net Income
-87.0M
↓ 25.87%
Net Profit Margin
-312.2%
↑ 686.8%
FY19Y/Y Change
Revenue
63.0M
↑ 126.28%
Net Income
-59.7M
↓ 31.33%
Net Profit Margin
-94.75%
↑ 217.45%
FY20Y/Y Change
Revenue
65.1M
↑ 3.34%
Net Income
-57.2M
↓ 4.17%
Net Profit Margin
-87.87%
↑ 6.88%
FY21Y/Y Change
Revenue
75.4M
↑ 15.81%
Net Income
-91.8M
↑ 60.36%
Net Profit Margin
-121.67%
↓ 33.8%
FY22Y/Y Change
Revenue
99.8M
↑ 32.25%
Net Income
-112.2M
↑ 22.2%
Net Profit Margin
-112.43%
↑ 9.24%
FY23Y/Y Change
Revenue
199.0M
↑ 99.42%
Net Income
-11.9M
↓ 89.36%
Net Profit Margin
-6.0%
↑ 106.43%
Q3 FY22Q/Q Change
Revenue
32.8M
↑ 73.73%
Net Income
-19.7M
↓ 37.36%
Net Profit Margin
-60.05%
↑ 106.49%
Q4 FY22Q/Q Change
Revenue
36.1M
↑ 9.85%
Net Income
-23.2M
↑ 17.88%
Net Profit Margin
-64.43%
↓ 4.38%
Q1 FY23Q/Q Change
Revenue
40.6M
↑ 12.67%
Net Income
-16.0M
↓ 31.07%
Net Profit Margin
-39.42%
↑ 25.01%
Q2 FY23Q/Q Change
Revenue
48.6M
↑ 19.65%
Net Income
-5.3M
↓ 67.13%
Net Profit Margin
-10.83%
↑ 28.59%
Q3 FY23Q/Q Change
Revenue
51.3M
↑ 5.43%
Net Income
1.7M
↓ 132.69%
Net Profit Margin
3.36%
↑ 14.19%
Q4 FY23Q/Q Change
Revenue
58.5M
↑ 14.09%
Net Income
1.4M
↓ 18.59%
Net Profit Margin
2.4%
↓ 0.96%
FY18Y/Y Change
Total Assets
107.7M
↑ 27.35%
Total Liabilities
282.8M
↓ 5.52%
FY19Y/Y Change
Total Assets
93.7M
↓ 12.98%
Total Liabilities
284.3M
↑ 0.52%
FY20Y/Y Change
Total Assets
108.6M
↑ 15.88%
Total Liabilities
289.0M
↑ 1.68%
FY21Y/Y Change
Total Assets
321.2M
↑ 195.71%
Total Liabilities
530.5M
↑ 83.55%
FY22Y/Y Change
Total Assets
295.3M
↓ 8.06%
Total Liabilities
545.8M
↑ 2.89%
FY23Y/Y Change
Total Assets
475.2M
↑ 60.93%
Total Liabilities
721.4M
↑ 32.16%
Q3 FY22Q/Q Change
Total Assets
293.8M
↑ 2.81%
Total Liabilities
531.5M
↓ 0.25%
Q4 FY22Q/Q Change
Total Assets
295.3M
↑ 0.49%
Total Liabilities
545.8M
↑ 2.69%
Q1 FY23Q/Q Change
Total Assets
298.1M
↑ 0.97%
Total Liabilities
553.5M
↑ 1.41%
Q2 FY23Q/Q Change
Total Assets
313.4M
↑ 5.13%
Total Liabilities
573.9M
↑ 3.68%
Q3 FY23Q/Q Change
Total Assets
320.3M
↑ 2.2%
Total Liabilities
572.1M
↓ 0.31%
Q4 FY23Q/Q Change
Total Assets
475.2M
↑ 48.35%
Total Liabilities
721.4M
↑ 26.09%
FY18Y/Y Change
Operating Cash Flow
-37.7M
↓ 41.75%
Investing Cash Flow
-234.0K
↓ 101.4%
Financing Cash Flow
61.3M
↓ 16.68%
FY19Y/Y Change
Operating Cash Flow
-88.5M
↑ 134.51%
Investing Cash Flow
-22.8M
↑ 9661.97%
Financing Cash Flow
69.9M
↑ 13.98%
FY20Y/Y Change
Operating Cash Flow
-28.1M
↓ 68.21%
Investing Cash Flow
15.2M
↓ 166.61%
Financing Cash Flow
49.9M
↓ 28.64%
FY21Y/Y Change
Operating Cash Flow
-61.7M
↑ 119.39%
Investing Cash Flow
-151.5M
↓ 1095.91%
Financing Cash Flow
270.3M
↑ 442.13%
FY22Y/Y Change
Operating Cash Flow
-80.7M
↑ 30.74%
Investing Cash Flow
4.9M
↓ 103.22%
Financing Cash Flow
21.4M
↓ 92.09%
Q3 FY22Q/Q Change
Operating Cash Flow
-28.1M
↓ 12.22%
Investing Cash Flow
27.3M
↑ 1252.52%
Financing Cash Flow
19.5M
↓ 1199.44%
Q4 FY22Q/Q Change
Operating Cash Flow
-2.4M
↓ 91.54%
Investing Cash Flow
15.0M
↓ 45.11%
Financing Cash Flow
2.8M
↓ 85.53%
Q1 FY23Q/Q Change
Operating Cash Flow
1.2M
↓ 148.65%
Investing Cash Flow
13.8M
↓ 8.11%
Financing Cash Flow
1.2M
↓ 59.15%
Q2 FY23Q/Q Change
Operating Cash Flow
2.6M
↑ 124.57%
Investing Cash Flow
3.7M
↓ 73.43%
Financing Cash Flow
-5.9M
↓ 615.16%

Technicals Summary

Sell

Neutral

Buy

Mannkind Corp. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Mannkind Corp.
Mannkind Corp.
-14.87%
3.47%
9.14%
-13.46%
166.24%
Moderna, Inc.
Moderna, Inc.
-1.15%
39.75%
-18.77%
-40.22%
304.34%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-7.56%
12.46%
14.48%
77.72%
159.17%
Novo Nordisk A/s
Novo Nordisk A/s
-2.8%
32.13%
52.48%
239.51%
414.16%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-4.96%
10.08%
23.01%
83.3%
130.08%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Mannkind Corp.
Mannkind Corp.
NA
NA
-0.23
0.13
0.0
0.02
NA
-0.91
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.22
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.04
26.04
1.46
45.0
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
47.43
47.43
2.4
3.35
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.81
28.81
0.53
16.75
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Mannkind Corp.
Mannkind Corp.
Buy
$1.1B
166.24%
NA
-6.0%
Moderna, Inc.
Moderna, Inc.
Buy
$41.7B
304.34%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$99.5B
159.17%
26.04
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$562.8B
414.16%
47.43
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$103.6B
130.08%
28.81
36.68%

Institutional Holdings

  • BlackRock Inc

    8.25%

  • Vanguard Group Inc

    5.64%

  • State Street Corporation

    4.79%

  • Nitorum Capital, L.P.

    4.01%

  • venBio Select Advisor LLC

    3.33%

  • Goldman Sachs Group Inc

    2.25%

Corporate Announcements

  • Mannkind Corp. Earnings

    Mannkind Corp.’s price-to-earnings ratio stands at None

    Read More

Company Information

mannkind corporation (nasdaq: mnkd) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. in addition, mannkind is applying our novel technologies and services to support partner development efforts.

Organization
Mannkind Corp.
Employees
411
CEO
Dr. Michael E. Castagna Pharm.D.
Industry
Health Technology

Discover More

FAQs